Planned System Maintenance
Starting Friday, December 21st, 2018 beginning at 5:00 PM EST, and ending on Friday, December 21st, 2018 at 11:00 PM EST. During this time there will be no access to the system including patient enrollments.
Please share this notification to the personnel who will be affected by this within your organization.
Maintenance Start: Friday, December 21st, 2018, 5:00 PM EST.
Maintenance End: Friday, December 21st, 2018, 11:00 PM EST.
We are sorry for any inconvenience this may cause.
December 05, 2018
 The MA37 (BIG 14-03) PALLAS Study "PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer" was closed to accrual as of November 30, 2018. Read More |
 The Pharmacist Network is actively seeking volunteers as Pharmacist Representatives for the Breast and Gastrointestinal Disease Site Committees. Participation in these opportunities earns volunteers a fully funded invitation to the annual CCTG Spring Meeting in Toronto. The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at: |
 The CCTG Central Office will be closed on specific dates during the holidays and there will be partial staff coverage on the dates indicated below. Web-based applications (i.e. MANGO, GCP) will be available. Regular business hours will resume on Wednesday, January 2, 2019 at 8:30 am EST. CCTG Holiday Hours Read More |
The IND.234 study advances personalized medicine for prostate cancer patientsPublished: December 05, 2018Category: News  At a press conference last week CCTG announced a new clinical trial, opening across Canada. IND.234 is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world. The IND.234 clinical trial, uses liquid biopsy technology to screen for genomic markers in prostate cancer patients. Read More |
The Canadian Partnership Against Cancer’s #30MinutesThatMatter campaignPublished: December 05, 2018Category: News  When it comes to cancer, a lot can happen in 30 minutes. Someone can have a life-changing appointment with their doctor, receive a supportive phone call from a peer or start cancer treatment. Now, thanks to the Canadian Partnership Against Cancer’s (the Partnership) #30MinutesThatMatter campaign, Canadians can also spend 30 minutes sharing their experiences with cancer to help modernize Canada’s cancer care plan. Read More |
November 21, 2018
 The CCTG BR.34 Trial: A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC) was closed to further accrual as of November 07, 2018. Read More |
|
|
 A video interview with Dr. Anna Spreafico who is the CCTG study chair for the HN.9 clinical trial. Read More |
